Jazz Pharmaceuticals Plc – Ordinary Shares (NASDAQ:JAZZ) Sellers Reduced By 6.31% Their Shorts As Of Jan 9, 2019

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Corporate Logo

During Q3 2018 the big money sentiment decreased to 1.28. That’s change of 0.24, from 2018Q2’s 1.52. 34 investors sold all, 100 reduced holdings as Jazz Pharmaceuticals plc ratio dived. 108 grew stakes while 63 funds acquired stakes. Funds hold 52.61 million shares thus 3.34% less from 2018Q2’s 54.43 million shares.
Pggm Invs holds 0.05% in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) or 51,110 shs. Parallax Volatility Advisers L P reported 0% in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Amp Capital Investors Ltd holds 0.01% of its capital in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) for 16,193 shs. Group One Trading L P holds 0.01% or 6,996 shs. State Of Wisconsin Invest Board reported 68,466 shs. Thomas White Ltd reported 4,300 shs. 1.12 million are held by Boston. Comerica Bancorporation stated it has 11,980 shs or 0.02% of all its holdings. Incorporated invested in 3,227 shs. Stevens Ltd Partnership reported 13,557 shs. Franklin Inc invested in 0.04% or 463,631 shs. Mirae Asset Global Limited, a Korea-based fund reported 27,213 shs. Monarch Prtnrs Asset Mngmt Ltd Liability Corp holds 0.87% or 57,140 shs. Apg Asset Management Nv stated it has 419,454 shs. Kornitzer Management Ks accumulated 0.05% or 17,293 shs.

Jazz Pharmaceuticals plc registered $3.21 million net activity with 1 buy and 17 sales since July 13, 2018. COZADD BRUCE C sold $213,668 worth of stock or 1,300 shs. On Friday, December 14 3,334 shs were sold by Hooper Suzanne Sawochka, worth $467,460. On Monday, September 17 $113,890 worth of stock was sold by Young Matthew P.. On Thursday, August 9 the insider O’Keefe Kenneth W sold $116,563. ENRIGHT PATRICK G also sold $1.71 million worth of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) on Thursday, September 6. Another trade for 200 shs valued at $31,692 was sold by MILLER MICHAEL PATRICK.

It was reported a decrease on Jazz Pharmaceuticals Plc – Ordinary Shares (NASDAQ:JAZZ)’s shorted shares with 6.31%. FINRA published in January JAZZ’s total 1.87M shorted shares. The 2.00M previous shares are down with 6.31%. Jazz Pharmaceuticals Plc – Ordinary Shares (NASDAQ:JAZZ) has 1.04M shares average volume. It’ll cost 2 days for JAZZ to restore its previous position. Float short on Jazz Pharmaceuticals Plc – Ordinary Shares is 3.18%.

JAZZ is hitting $131.31 during the last trading session, after increased 2.52%.Jazz Pharmaceuticals plc has volume of 527,893 shares. Since January 9, 2018 JAZZ has risen 3.57% and is uptrending. The stock outperformed the S&P500 by 3.57%.

Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally.The firm is worth $7.92 billion. The firm has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.15.51 is the P/E ratio. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Ratings Coverage

Total analysts of 6 have positions in Jazz Pharmaceuticals (NASDAQ:JAZZ) as follows: 5 rated it a “Buy”, 0 with “Sell” and 1 with “Hold”. The positive are 83%. Since July 10, 2018 according to StockzIntelligence Inc Jazz Pharmaceuticals has 6 analyst reports. On Wednesday, August 8 the firm has “Outperform” rating by BMO Capital Markets given. On Tuesday, July 10 Citigroup maintained Jazz Pharmaceuticals plc (NASDAQ:JAZZ) with “Buy” rating. On Wednesday, August 8 Stifel Nicolaus maintained the shares of JAZZ in report with “Buy” rating. The company rating was downgraded by Morgan Stanley on Wednesday, July 11. On Thursday, November 8 the firm has “Buy” rating by FBR Capital given.

There’s a substantial Jazz Pharmaceuticals plc (NASDAQ:JAZZ) news posted by Seekingalpha.com. It’s an item titled: “Your Daily Pharma Scoop: Jazz Reports Mixed Bag, Roche And Takeda Positive – Seeking Alpha” on July 23, 2018.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.